Dr. Pravin U. Dugel from Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration in a Healio Video Perspective from the ASRS meeting. The implant is designed to address unmet needs in sustainability and improve outcomes for patients. Dr. Dugel, who is the executive chairman, CEO, and president of Ocular Therapeutix, believes that this new treatment will not only improve sustainability but also allow for the treatment of more patients who deserve it. The phase 3 program shows promise for addressing the needs of patients with wet age-related macular degeneration.
Source link
Axitinib implant addresses sustainability in wet AMD
